{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:18:39Z","timestamp":1783678719994,"version":"3.55.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Recent studies have suggested an increased risk of prostate cancer in men with Lynch syndrome driven by germline mutations in mismatch repair (MMR) genes. However, the incidence and clinical implication of MMR deficiency in sporadic prostate cancers remain poorly understood. We immunohistochemically stained for MLH1, MSH2, MSH6, and PMS2 in a set of tissue microarray consisting of 220 radical prostatectomy specimens and evaluated the relationship between loss of their expression and available clinicopathological features. MLH1, MSH2, MSH6, and PMS2 were lost in 2 (0.9%), 6 (2.7%), 37 (16.8%), and 27 (12.3%) prostate cancers, respectively. Loss of at least 1 MMR protein was identified in 50 (22.7%) cases. There were no statistically significant associations between MMR deficiency and patient age, family history of prostate cancer, Gleason score, or pT\/pN stage. Nonetheless, the levels of preoperative prostate-specific antigen (PSA) were significantly (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.015) higher in patients with MMR deficiency (mean\u200a\u00b1\u200aSD: 9.12\u200a\u00b1\u200a9.01\u200ang\/mL) than in those without abnormal MMR (5.76\u200a\u00b1\u200a3.17\u200ang\/mL). There were 15 (6.8%) cases showing loss of at least 2 MMR proteins, which was not significantly associated with PSA level or tumor grade\/stage. Additionally, 5 and 2 cases showed losses of at least 3 MMR proteins and all 4 proteins, respectively. Kaplan\u2013Meier analysis revealed no significant associations between loss of MLH1 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.373), MSH2 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.348), MSH6 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.946), or PMS2 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.681), or at least 1 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.477), 2 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.486), or 3 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.352) MMR proteins and biochemical recurrence. Further analyses of the data on programmed death-ligand 1 (PD-L1) expression previously stained in the same set of tissue microarray demonstrated associations between loss of \u22652 MMR proteins and a higher rate of PD-L1 expression in cancer cells (17.2% vs 5.2%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.033) as well as between cases showing both loss of \u22651 MMR protein(s) and PD-L1 expression in tumor-infiltrating immune cells vs a higher risk of biochemical recurrence (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.045). MMR protein loss was seen in a subset of prostate cancers. Interestingly, it was associated with significantly higher levels of PSA. Moreover, immunohistochemical detection of MMR proteins together with other proteins, such as PD-L1, might be helpful in predicting tumor recurrence following radical prostatectomy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020124","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:36:39Z","timestamp":1588970199000},"page":"e20124","source":"Crossref","is-referenced-by-count":31,"title":["Loss of DNA mismatch repair proteins in prostate cancer"],"prefix":"10.1097","volume":"99","author":[{"given":"Meenal","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-7769","authenticated-orcid":false,"given":"Hiroshi","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"},{"name":"Department of Urology"},{"name":"James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5]]},"reference":[{"key":"R1-20240308","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R2-20240308","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"key":"R3-20240308","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/fon.15.318","article-title":"Biomarkers in localized prostate cancer","volume":"12","author":"Ferro","year":"2016","journal-title":"Future Oncol"},{"key":"R4-20240308","first-page":"3048","article-title":"Genetics, diagnosis and treatment of Lynch syndrome: old lessons and current challenges (Review)","volume":"17","author":"Duraturo","year":"2019","journal-title":"Oncol Lett"},{"key":"R5-20240308","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/jnci\/djs351","article-title":"Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome","volume":"104","author":"Win","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"R6-20240308","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","article-title":"Elevated risk of prostate cancer among men with Lynch syndrome","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"key":"R7-20240308","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1038\/ncomms5988","article-title":"Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer","volume":"5","author":"Pritchard","year":"2014","journal-title":"Nat Commun"},{"key":"R8-20240308","doi-asserted-by":"crossref","first-page":"82504","DOI":"10.18632\/oncotarget.12697","article-title":"Mismatch repair deficiency may be common in ductal adenocarinoma of the prostate","volume":"7","author":"Schweizer","year":"2016","journal-title":"Oncotarget"},{"key":"R9-20240308","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1172\/JCI121924","article-title":"Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer","volume":"128","author":"Rodrigues","year":"2018","journal-title":"J Clin Invest"},{"key":"R11-20240308","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","article-title":"Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations","volume":"75","author":"Antonarakis","year":"2019","journal-title":"Eur Urol"},{"key":"R12-20240308","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1158\/1078-0432.CCR-17-0955","article-title":"MSH2 loss in primary prostate cancer","volume":"23","author":"Guedes","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R13-20240308","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00428-019-02591-z","article-title":"Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status","volume":"475","author":"Albero-Gonz\u00e1lez","year":"2019","journal-title":"Virchows Arch"},{"key":"R14-20240308","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/pros.21323","article-title":"Expression of semenogelins I and II and its prognostic significance in human prostate cancer","volume":"71","author":"Canacci","year":"2011","journal-title":"Prostate"},{"key":"R15-20240308","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.humpath.2012.02.008","article-title":"Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy","volume":"43","author":"Izumi","year":"2012","journal-title":"Hum Pathol"},{"key":"R16-20240308","doi-asserted-by":"crossref","first-page":"e17257","DOI":"10.1097\/MD.0000000000017257","article-title":"Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer","volume":"98","author":"Sharma","year":"2019","journal-title":"Medicine"},{"key":"R17-20240308","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/carcin\/bgw116","article-title":"Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer","volume":"38","author":"Wilczak","year":"2017","journal-title":"Carcinogenesis"},{"key":"R18-20240308","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mrfmmm.2012.12.008","article-title":"Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities","volume":"743-744","author":"Edelbrock","year":"2013","journal-title":"Mutat Res"},{"key":"R19-20240308","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.celrep.2016.03.075","article-title":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","volume":"15","author":"Giannakis","year":"2016","journal-title":"Cell Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:14:11Z","timestamp":1709928851000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":18,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020124","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}